SEC Form 4 · accession 0001918845-26-000031
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mittie Doyle
Officer — Chief Medical Officer
Period of report
Aug 28, 2026
Accepted (ET)
Sep 1, 2026 · 4:38 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001534120
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 28, 2026 | M | 679 | $8.04 | A | 52,455 | D | |
| Common Stock | Aug 28, 2026 | S | 679 | $20.00 | D | 51,776 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $8.04 | Aug 28, 2026 | M | 679 | D | — | Jan 28, 2035 | Common Stock | 679 | 113,734 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.